238 related articles for article (PubMed ID: 27351637)
1. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies.
Palmaro A; Moulis G; Despas F; Dupouy J; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2016 Dec; 30(6):616-624. PubMed ID: 27351637
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoepidemiological research using French reimbursement databases: yes we can!
Martin-Latry K; Bégaud B
Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):256-65. PubMed ID: 20128015
[TBL] [Abstract][Full Text] [Related]
3. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database.
Latry P; Molimard M; Bégaud B; Martin-Latry K
Eur J Clin Pharmacol; 2010 Jul; 66(7):743-8. PubMed ID: 20429000
[TBL] [Abstract][Full Text] [Related]
4. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.
Bezin J; Duong M; Lassalle R; Droz C; Pariente A; Blin P; Moore N
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):954-962. PubMed ID: 28544284
[TBL] [Abstract][Full Text] [Related]
5. [Terminology used in publications of pharmacoepidemiological research in france using health insurance reimbursement databases: need for harmonisation].
Martin-Latry K; Cougnard A
Therapie; 2010; 65(4):379-85. PubMed ID: 20854762
[TBL] [Abstract][Full Text] [Related]
6. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
Conte C; Vaysse C; Bosco P; Noize P; Fourrier-Reglat A; Despas F; Lapeyre-Mestre M
Therapie; 2019 Apr; 74(2):279-288. PubMed ID: 30824175
[TBL] [Abstract][Full Text] [Related]
7. Homeopathy in France in 2011-2012 according to reimbursements in the French national health insurance database (SNIIRAM).
Piolot M; Fagot JP; Rivière S; Fagot-Campagna A; Debeugny G; Couzigou P; Alla F
Fam Pract; 2015 Aug; 32(4):442-8. PubMed ID: 25921648
[TBL] [Abstract][Full Text] [Related]
8. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.
Noize P; Bazin F; Dufouil C; Lechevallier-Michel N; Ancelin ML; Dartigues JF; Tzourio C; Moore N; Fourrier-Réglat A
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):310-9. PubMed ID: 19241438
[TBL] [Abstract][Full Text] [Related]
9. [Technical improvement of cohort constitution in administrative health databases: Providing a tool for integration and standardization of data applicable in the French National Health Insurance Database (SNIIRAM)].
Ferdynus C; Huiart L
Rev Epidemiol Sante Publique; 2016 Sep; 64(4):263-9. PubMed ID: 27592033
[TBL] [Abstract][Full Text] [Related]
10. Use of French healthcare insurance databases in pediatric pharmacoepidemiology.
Kaguelidou F; Sommet A; Lapeyre-Mestre M
Therapie; 2018 Apr; 73(2):127-133. PubMed ID: 29588074
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacoepidemiology. Analysis of drug prescription data].
Gothe H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Oct; 51(10):1145-54. PubMed ID: 18985408
[TBL] [Abstract][Full Text] [Related]
12. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution.
Dupui M; Micallef J; Lapeyre-Mestre M
Therapie; 2019 Apr; 74(2):307-314. PubMed ID: 30798951
[TBL] [Abstract][Full Text] [Related]
13. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database.
Garbe E; Suling M; Kloss S; Lindemann C; Schmid U
Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):258-64. PubMed ID: 21351307
[TBL] [Abstract][Full Text] [Related]
14. The Nordic countries as a cohort for pharmacoepidemiological research.
Furu K; Wettermark B; Andersen M; Martikainen JE; Almarsdottir AB; Sørensen HT
Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):86-94. PubMed ID: 19961477
[TBL] [Abstract][Full Text] [Related]
15. Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database.
Conte C; Rueter M; Laurent G; Bourrel R; Lapeyre-Mestre M; Despas F
Support Care Cancer; 2016 Nov; 24(11):4791-9. PubMed ID: 27435321
[TBL] [Abstract][Full Text] [Related]
16. Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives.
Revet A; Moulis G; Raynaud JP; Bui E; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2022 Feb; 36(1):16-34. PubMed ID: 33998708
[TBL] [Abstract][Full Text] [Related]
17. [Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice].
de Germay S; Conte C; Micallef J; Bouquet E; Chouchana L; Lafaurie M; Pariente A;
Therapie; 2023; 78(6):691-703. PubMed ID: 36841652
[TBL] [Abstract][Full Text] [Related]
18. A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs.
Larsen MD; Cars T; Hallas J
Basic Clin Pharmacol Toxicol; 2013 Jan; 112(1):13-8. PubMed ID: 22901097
[TBL] [Abstract][Full Text] [Related]
19. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.
Tuppin P; Rudant J; Constantinou P; Gastaldi-Ménager C; Rachas A; de Roquefeuil L; Maura G; Caillol H; Tajahmady A; Coste J; Gissot C; Weill A; Fagot-Campagna A
Rev Epidemiol Sante Publique; 2017 Oct; 65 Suppl 4():S149-S167. PubMed ID: 28756037
[TBL] [Abstract][Full Text] [Related]
20. French health insurance databases: What interest for medical research?
Moulis G; Lapeyre-Mestre M; Palmaro A; Pugnet G; Montastruc JL; Sailler L
Rev Med Interne; 2015 Jun; 36(6):411-7. PubMed ID: 25547954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
